NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Forecast & News

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings data on Tuesday, February, 25th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by $0.04. Vanda Pharmaceuticals had a net margin of 55.49% and a return on equity of 38.90%. View Vanda Pharmaceuticals' Earnings History.

Vanda Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $240-260 million, compared to the consensus revenue estimate of $274.55 million.

3 equities research analysts have issued twelve-month target prices for Vanda Pharmaceuticals' stock. Their forecasts range from $17.00 to $19.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $18.00 in the next twelve months. This suggests a possible upside of 56.9% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vanda Pharmaceuticals.

News articles about VNDA stock have been trending very negative on Wednesday, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Vanda Pharmaceuticals.

Vanda Pharmaceuticals saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 4,010,000 shares, a decline of 10.3% from the December 31st total of 4,470,000 shares. Based on an average daily volume of 556,300 shares, the short-interest ratio is currently 7.2 days. Currently, 7.8% of the shares of the stock are short sold. View Vanda Pharmaceuticals' Current Options Chain.

Some companies that are related to Vanda Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Array Biopharma (ARRY), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Crispr Therapeutics (CRSP) and ImmunoGen (IMGN).

Vanda Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Palo Alto Investors LP (8.48%), Renaissance Technologies LLC (6.47%), State Street Corp (4.75%), Prudential Financial Inc. (2.37%), Acadian Asset Management LLC (1.85%) and Geode Capital Management LLC (1.43%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Institutional Ownership Trends for Vanda Pharmaceuticals.

VNDA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Goldman Sachs Group Inc., FMR LLC, Charles Schwab Investment Management Inc., Rafferty Asset Management LLC, 361 Capital LLC, Pictet Asset Management Ltd. and Palo Alto Investors LP. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Insider Buying and Selling for Vanda Pharmaceuticals.

VNDA stock was acquired by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC, Bank of Montreal Can, Acadian Asset Management LLC, Man Group plc and Panagora Asset Management Inc.. View Insider Buying and Selling for Vanda Pharmaceuticals.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $11.47.

Vanda Pharmaceuticals has a market capitalization of $611.78 million and generates $193.12 million in revenue each year. The biopharmaceutical company earns $25.20 million in net income (profit) each year or $0.48 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.View Additional Information About Vanda Pharmaceuticals.

The official website for Vanda Pharmaceuticals is http://www.vandapharma.com/.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]